Technology in Diabetes Management Irl B. Hirsch, MD University of Washington
|
|
- Gervais Gilbert
- 5 years ago
- Views:
Transcription
1 Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington
2 Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia
3 Raise Your Hand If In Your Practice Every patient gets their meter downloaded Every patient gets their pump downloaded Every patient gets their CGM downloaded No patient gets downloaded, but you encourage your patients to download at home If you have at least one computer designated for downloading If your downloads are uploaded into your EMR
4 Required (or at least desirable) Infrastructure for Your Office Person knowledgeable with insurance/payers, PAs, verbiage to efficiently gain approval Person (doesn t have to be CDE) who can train patients; pros and cons of using all industry support Coming soon? Kiosks in the waiting room for patients to download their own technology Mechanisms (stickers) to ensure technologies do not get mixed up Dedicated computer(s) for downloading
5 What You Need (Minimal) A program which allows downloading of various meters/pumps/sensors Clinipro (Numedics.com), Glooko/Diasend, Carelink, Tidepool Ideally, many of the native softwares are also available A better solution: immediate upload to the cloud Livongo, Accucheck Aviva Connect, Dexcom Clarity
6 Metrics in Diabetes Meaningful Use (performance metrics) Glucometrics : analysis of blood glucose data To better understand the glycemic fingerprint of each individual patient: A1C, mean, SD, CV, TIR, LBGI What we always seem to be doing in diabetes: updating the metrics ( work in progress )
7 Standard Deviation Our clinically available measurement of glycemic variability for both SMBG and CGM Many other statistical analysis are available but correlation will be with CGM and outcomes, not SMBG (current studies using CV) Can determine both overall and time specific SD SMBG: Need sufficient data points Minimum 5 but prefer 10
8 Calculation To Determine SD Target SMBG SD X 3 < MEAN SD X 2 < mean, may be difficult for some type 1 patients. Formulas only relevant for mean BG between CGM SD X 3 < MEAN Need better metrics: CV, TIR, TBR, TAR all to be correlated with outcomes
9 CASE 1: Christie 32 y/o woman on 8 units glargine BID with pre meal lispro 1:15, ISF 50 day, 60 at HS; jogs at 7am 5X s/week; b fast at 8a, lunch at 1p, dinner at 7p Mean/SD 126/47; A1C 6.0% 1. Too much basal Too much prandial with downward trend As is often the case, the A1C doesn t reflect all of the major challenges are patients are having Poor prandial replacement
10 CASE 2 45 y/o Ethiopean man moved to Seattle to work as an executive for a coffee company (we don t have Dunkin Donuts in Seattle) T2DM X 10 years, on insulin X8 years BMI 36; A1C 8.7% Has been on SAP for 4 years
11 SEPT 2014:MEAN 197; SD 75; A1C = 8.7%
12 Good basal BC: 17U BC: 11.5 U 60 g CHO 44 g CHO Stayed high: last bolus not enough No bolus: too much basal? Insulin given with food Insulin given with food
13 With All of This Technology, His Major Problem (or Should Be) is Easy to Fix Insulin needs to be given before one eats! Why is this so difficult for so many patients?
14 So What Happened To Our Patient s Diabetes Over the Next Two Years? OCT 2016: Mean = 156; SD = 41; A1C = 7.1%
15 CSII: What Does The Clinical Endocrinologist Need To Know in 2016?
16 Features of CSII: Evolution Over the Years Many basal (alternating, temp) and bolus (extended, 2 component) options but to me, the most important ones both grossly under utilized by patient and provider: Downloading both for patients and providers. Bolus calculator: when used appropriately is a tremendous tool!
17 The Problem with Bolus Calculators They are not smart! If the glucose is trending up or down, more or less insulin will be required Estimate Details: Bolus Calculator Est. total 4.5 U Food intake 36 g (meter) BG 210 Food 3 U Correction 2 U IOB 0.5 U
18 Like With Pumps, We ve Come A Long Way With CGM
19 Sensors: Continual Evolution For the Near Future Guardian Sensor 3 Freestyle Libre Roche Glucose Sensor Dexcom Gen 6 Sensionics Implantable Sensor
20 Medtronic Sensors For the Next 5 Years
21 What is AP? CGM + Pump + Controller Controller: laptop, tablet, phone to start, chips will get smaller
22 Our Current Pathway to AP (Closed Loop)
23 Past, Present, and Future of CSII/AP CSII LGS and PGS Lancet Diabetes Endocrinology 2014; 2: SAP Nocturnal CL HCL LB 99 ADA, 2016
24 ARTIFICIAL PANCREAS
25 What is Hybrid Closed Loop? Patient still needs to bolus for meals and notify the system for exercise. Medtronic 670G approved for release in 2017
26 Medtronic 670G Pivotal Trial ADA Scientific Sessions 2016, Bergenstal, Buckingham, Garg et al: 99 LB Single arm, non randomized, 3 months N = 124 (n=94 adults, 30 adolescents) Baseline A1C 7.4%; mean reduction 0.5% Those with baseline > 7.5% reduction by 1.0% Time < 70 mg/dl reduced by 44%, < 50 mg/dl by 40% Time in range increased 72% 1.4 kg weight increase in adults, 1.0 kg weight gain in adolescents MARD 10.3%
27 All patients
28 Adolescents
29 More Information About the 670G No control group: an up coming 1000 patient trial is planned Two on going pediatric studies in 7 14 year olds and 2 6 year olds DreaMed MD Logic (Fuzzy Logic): incorporate automatic correction doses: bridge funding from NIH secured. This product will be called Medtronic 690G
30 IBM Watson (appears to be positioned more for non CL patients)
31 More To Think About with our First HCL Psycho social studies now on going: little now known how will this impact QOL for needing to unlearn behaviors (eg., hypo Rx with down arrow) Are expectations too high, especially for clinicians in non centers of excellence? What about type 1 patients not seen by endocrinologists. How will the elderly do with this technology?
32 Components of a Bi Hormonal AP (Bionic Pancreas) Are 2 hormones better than 1? Are we better off with glucagon, pramlintide, or GLP 1?
33 Finally: Some Data For What We ve All Been Wondering! N = 10; CL, then 4 weeks 60 mcg PRAM ac Mean age 20 years, 9 years T1D, A1C 7.2% N = 11: CL, then 4 weeks 1.8 mg daily LIRA Mean age 22 years, 10.5 years T1D, A1C 7.5% Meals were not announced Diabetes Care 2016;39:
34 CL vs. CL + PRAM or LIRA Adjunctive Rx: Purple Control: Green Diabetes Care 2016;39:
35 CL vs. CL + PRAM or LIRA CL vs. CL + PRAM CL vs. CL + LIRA P< Time to Peak G (h) P=NS Time to peak G (h) CL alone CL + PRAM CL alone CL + LIRA CL vs. CL + PRAM CL vs. CL + LIRA P< P= Glucose Spike Glucose spike CL CL + LIRA CL CL+PRAM Diabetes Care 2016;39:
36 CL vs. CL + PRAM or LIRA TIR during daytime better with PRAM (p<0.004) but not LIRA (p=ns). Neither drug with better TIR overnight LIRA: better weight loss (3.2 kg) compared to PRAM (0.7 kg) Longer term studies with these adjunctive agents are warranted. Diabetes Care 2016;39:
37 But What About Glucagon? Would this be a better adjunctive hormone to infuse in a CL system?
38 Bihormonal AP 2014
39 ẞeta ẞionics 2016
40 Bionic Pancreas with 6 11 Year Old Children at Diabetes Camp Lancet Diabetes Endocrinol 2016;4:233 43
41 Mean CGM and Percentage <70 mg/dl Bionic Pancreas vs Usual Care (Adults) <70 = 7.3% <60 = 3.7% 2016: stable liquid glucagon analogue: ZP4207 from Zealand Pharmaceuticals <70 = 4.1% <60 = 1.5% Russell et al. New Engl J Med 2014; 371:
42 This is All VERY Exciting, but What Does All of This Mean for the Endocrinologist in Practice? Non pediatric, non academic endocrinologists Few (less than 10%) do any pump/sensor downloading, so unable to really see patterns/understand the granularity how the patient is managing the diabetes For many (number now known) much if not most of the training, insulin adjustments, management done by industry or non physician (often CDE) Unfortunately, this is so time consuming and there is so much more pressure to be productive, it isn t time efficient for many of us to routinely manage these patients Few learn to be experts in this therapy in their training
43 My Questions Could a more automated pump system make the therapy simpler and more efficient so both clinical endocrinologists and non specialists can easily oversee closed loop systems with better A1C levels with less hypoglycemia? OR, will this create a greater clinical burden making this therapy an even greater hassle requiring more infrastructure than it does now? Raise your hand if you think the administrative burden managing this therapy from your offices and clinics will be MORE than it is now! Will payers want to pay for this if the cost is more than a pump and sensor alone? (BTW many Medicaid patients in WA state are now back on human insulin)
44 One Other Point In the US, about 30% of our type 1 patients use CSII (60% in the T1D Exchange) and most agree the majority of adult type 1 patients receive their care from a nonspecialist The majority of patients use MDI will this therapy increase CSII use for those who are cared for by both endocrinologists and non specialists? 2 studies at 2016 ADA: outcomes improved with CGM and MDI
45 What About the 70% of T1D Who Use MDI? Companion Medical InPen system Approved by FDA 8/16, to be launched 2017 Will track prandial insulin doses (cartridge pens) and send to paired app via Bluetooth App also includes a bolus calculator (with real time IOB)
46 What does it look like?
47 Conclusion We are at a crossroads in the evolution of our pumps and sensors. While the technology for a HCL may be available within the next year, a true CL hopefully will be close behind Still, there are many questions that need to be answered: 1 vs. 2 hormones, which 2 nd hormone and how would each do in a pump, site failures, skin problems, cost, work flow, psycho social issues, CGM accuracy, etc., etc, etc Still, these are better questions than we had 5 years ago
CGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationDiabetes Technology for the Endocrinologist, Irl B. Hirsch, MD University of Washington
Diabetes Technology for the Endocrinologist, 2017 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia, Adocia,
More informationUsing and Interpreting Diabetes Data. Irl B. Hirsch, MD University of Washington
Using and Interpreting Diabetes Data Irl B. Hirsch, MD University of Washington Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas,
More informationApplications of Technologies to Your Patient. Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington
Applications of Technologies to Your Patient Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington Disclosures Consultant: Abbott Diabetes Care, Roche
More informationPump and Sensor Data Interpretation. Irl B. Hirsch, MD University of Washington School of Medicine
Pump and Sensor Data Interpretation Irl B. Hirsch, MD University of Washington School of Medicine Dualities Research: Medtronic Diabetes Consulting: Abbott Diabetes Care, BD, Bigfoot, Roche Raise Your
More informationDiabetes Technology in Irl B. Hirsch, MD University of Washington School of Medicine Seattle, WA
Diabetes Technology in 2018 Irl B. Hirsch, MD University of Washington School of Medicine Seattle, WA Dualities Research: Medtronic Diabetes Consulting: Abbott Diabetes Care, BD, Bigfoot, Roche Let s First
More informationDr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting
Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting Disclaimers None Except products and software discussed are all proprietary, so if I mention a brand product it is because there is no other
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationUpdate on Diabetes Technology
Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationEmerging Automated Insulin Delivery Systems
Emerging Automated Insulin Delivery Systems Richard M. Bergenstal, MD International Diabetes Center Park Nicollet & HealthPartners Minneapolis, MN Presenter Name 1 Dualities: Richard M. Bergenstal, MD
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationMaking Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017
HSW1 Disclosure to Participants Making Sense of Glucose Monitoring Alison B. Evert, MS, RD, CDE UW Neighborhood Clinics UW Medicine Seattle, WA Conflict of Interest (COI) and Financial Relationship Disclosures:
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationMaking the Most of Continuous Glucose Monitoring
Making the Most of Continuous Glucose Monitoring Gary Scheiner MS, CDE Owner & Clinical Director Integrated Diabetes Services LLC Wynnewood, PA AADE 2014 Diabetes Educator of the Year gary@integrateddiabetes.com
More informationFuture Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationAdvances Towards the Bionic Pancreas.
Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated
More informationThe artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes
The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes Roman Hovorka PhD FMedSci University of Cambridge, UK Duality of interest declaration Advisory Panel: Research
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationObjectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018
Objectives Innovations in Diabetes Care and Management Barbara Walz, RN, BSN, CDE April 26, 2018 1. Briefly discuss the history of diabetes management over the past 100 years 2. Describe the impact of
More informationOBJECTIVES THE PAST INNOVATIVE TECHNOLOGY & DIABETES DIABETES MIS MANAGEMENT IMPROVEMENTS IN DIABETES MANAGEMENT
OBJECTIVES INNOVATIVE TECHNOLOGY & DIABETES TRISHA PORRETTI, RN, BSN, CDE PWD FOR 25 YEARS Identify important safety features and differences of 3 Continuous Glucose Monitoring (CGM) systems Identify important
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationNEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center
NEWS BRIEFING Advances in Technology moderated by: Irl Hirsch, MD University of Washington Medical Center 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationJDRF Perspective on Closed Loop
JDRF Perspective on Closed Loop Aaron J. Kowalski, Ph.D. Assistant Vice President Treatment Therapies Juvenile Diabetes Research Foundation International 1 Presenter Disclosure Aaron Kowalski Disclosed
More informationContinuous Glucose Monitors for Diabetes Management
Continuous Glucose Monitors for Diabetes Management Ryan Huang, DO PGY II, Sonia Garcia-Jayne, DO PGY II Mandeep Gill, DO PGY I, Justin Leeka, DO, PGY I, Catherine Nguyen OMS IV Family Medicine Residency,
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationDiabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013
Diabetes through my eyes Rick Mauseth, M.D. W.A.D.E. April 2013 Ant hills Total Available Glucose utilized Two drops of urine in test tube Add 10 drops of water Added tablet Foamed and got hot Compared
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More information5/18/2010. History of 1,5 Anhydroglucitol (1,5 AG) Glucose Variability & Pattern Management: Way Beyond Logbooks. Normal Renal Glucose Handling
Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA Normal Renal Handling 180 g of glucose is filtered each day Virtually all glucose reabsorbed
More informationGlucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA
Glucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA 1 Normal Renal Glucose Handling 180 g of glucose is filtered each day Virtually all
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationAdvances in Diabetes Technology Part II: Analysis of Diabetes Self Management Devices and Support Tools
Advances in Diabetes Technology Part II: Analysis of Diabetes Self Management Devices and Support Tools Jennifer Trujillo, PharmD, FCCP, BCPS, CDE, BC ADM Associate Professor University of Colorado School
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationArtificial Pancreas, shortly close to home? BC Pediatric Diabetes Day, Feb 26, 2016
Artificial Pancreas, shortly close to home? BC Pediatric Diabetes Day, Feb 26, 2016 Rémi Rabasa- Lhoret, M.D. (Endocrinology), Ph.D. CSPQ Director Pla:orm for Research in Obesity, Metabolism and Diabetes
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationGlucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets
Devices Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets Accuracy Glucometers The ISO (International Organization for
More informationHybrid Closed Loop Status & Practical Challenges in Implementation
Hybrid Closed Loop Status & Practical Challenges in Implementation Bruce Buckingham, MD Buckingham@Stanford.edu Professor of Pediatric Endocrinology Stanford School of Medicine Conflict of Interests Company
More informationDIABETES TECHNOLOGY: ENDLESS CHOICES FOR HEALTHY MANAGEMENT
DIABETES TECHNOLOGY: ENDLESS CHOICES FOR HEALTHY MANAGEMENT MAKING THE MOST OF MODERN DIABETES TREATMENTS & TECHNOLOGIES JENNIFER C. SMITH RD, LD, CDE DIRECTOR OF LIFESTYLE AND NUTRITION INTEGRATED DIABETES
More informationADVANCES IN DIABETES TECHNOLOGY: A FOCUS ON CONTINUOUS GLUCOSE MONITORING 9:15 10:15 AM
ADVANCES IN DIABETES TECHNOLOGY: A FOCUS ON CONTINUOUS GLUCOSE MONITORING 9:15 10:15 AM ACPE UAN: 0107-9999-18-124-L01-P 0.1 CEU/1 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists:
More information7/18/2017. Everything discussed in this presentation is off-label. (And that s ok.) Dana Lewis Founder, #OpenAPS WARNING: Disclosure to Participants
Dana Lewis Founder, #OpenAPS Seattle, WA Disclosure to Participants Notice of Requirements For Successful Completion Please refer to learning goals and objectives Learners must attend the full activity
More informationSubject Index. Breastfeeding, self-monitoring of blood glucose 56
Subject Index Animas Vibe 86, 130 Artificial pancreas clinical studies inpatient studies 175 180 outpatient studies outcome assessment 182, 183 technology 180, 181 telemedicine 182 components glucose sensor
More informationADA 2018 JUN 25, 2018 ORLANDO, FLORIDA
ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions and expectations that involve uncertainties
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationTechnology in Diabetes Care: Emerging Level
Technology in Diabetes Care: Emerging Level Charlotte Parsons ARNP, CDE Christine Fisher, RD, CD, CDE, CPT WADE April 26, 2019 Disclosures to Participants Notice of Requirements for Successful Completion:
More informationWHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE
WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE MAY 5, 2018 OBJECTIVES Strong understanding of diabetes and its management
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationKathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018
Kathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018 Ksenia Tonyushkina, MD 1 Objectives What does it mean to live with T1DM? Why exercise is important?
More informationUvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication
UvA-DARE (Digital Academic Repository) The artificial pancreas Kropff, J. Link to publication Citation for published version (APA): Kropff, J. (2017). The artificial pancreas: From logic to life General
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 07/10/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationReal-Time Continuous Glucose Monitoring: From Application to Evaluation
Real-Time Continuous Glucose Monitoring: From Application to Evaluation Gary Scheiner MS, CDE Owner/Director, Integrated Diabetes Services 333 E. Lancaster Ave., Suite 24 Wynnewood, PA 1996 (877) 735-3648
More informationAbbott FreeStyle Libre Pro System
, the Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:
More informationOptimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL
Optimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL Welcome and Introduction Orlando, FL August 7 th, 2014 Keri Weindel,
More informationBASICS OF INSULIN PUMPS. Jennifer Okemah MS RD BCADM CDE CSSD
BASICS OF INSULIN PUMPS Jennifer Okemah MS RD BCADM CDE CSSD SPEAKER DISCLOSURES: Contracted trainer for Animas, Omnipod, Medtronic Dexcom Advisory Board Sanofi Advisory Board Sanofi Contracted Speaker
More informationDIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT
DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT Min-Jye Chen, MD Endocrinology Diabetes Management of the School-Aged Child Provided by Texas Children s Hospital Provider #18-267764-A
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationQUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?
500 1 QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3? WHAT ADDITIONAL DATA ARE NEEDED? AACE/ACE CGM Consensus Conference:
More informationTried and True Tips. Common BG Patterns & Fixes 11/2/16. Tried and True Tips and New Advances in Diabetes. The Right Number of Carbs for a Low
Tried and True Tips and New Advances in Diabetes San Diego Pump Club, Oct 1, 216 John Walsh PA, CDTC Tried and True Tips How Basal Rate Change Affects BG 1.7 Total Units When You Change a Basal Rate When
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationThe next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationThe Artificial Pancreas
SAGLB.DIA.15.2.87(2). Approved October 215 The Artificial Pancreas For scientific and medical purposes only The pancreas responds to changes in blood glucose by releasing insulin (β cells) to lower blood
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 05/24/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More information15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016
15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016 Sponsored by: Abbott Diabetes Care and Lilly Diabetes Type 1 and exercise Royal Berkshire Hospital Centre for Diabetes and Endocrinology
More informationHow I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary
How I use the latest technology to investigate and treat a person with Type 1 Diabetes Dr Pratik Choudhary Disclosures Advisory board and speaker fees from Medtronic, Roche, Abbott and Johnson and Johnson,
More informationAmbulatory Artificial Pancreas Platform (AAPP) User Manual
Ambulatory Artificial Pancreas Platform (AAPP) User Manual Welcome to the Artificial Pancreas User Manual. This manual is intended to teach you how to use the system in your clinical trial. If questions
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationDoes Technology helps adolescents with type 1 diabetes in fasting Ramadan?
Does Technology helps adolescents with type 1 diabetes in fasting Ramadan? Abdulmoein Al-Agha, FRCPCH Professor of Paediatric Endocrinology, King Abdulaziz University Hospital, http://aagha.kau.edu.sa
More informationContinuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients
ssociation of Children s Diabetes Continuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients 1 ssociation of Children s Diabetes Contents Chapter Page no. Chapter
More informationPeople with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT
Position Statement People with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT Diabetes Australia believes that people with diabetes should have choice and access
More informationFor Safe and Effective Diabetes Management
For Safe and Effective Diabetes Management How FreeStyle Libre Works FreeStyle Libre is a system for continuous glucose monitoring (CGM) that gives you easy access to your glucose numbers. CGM has been
More informationContinuous Glucose Monitoring Devices Pharmacy Policy
Line of Business: All Line of Business Effective date: August 16, 2017 Revision date: August 16, 2017 Continuous Glucose Monitoring Devices Pharmacy Policy This policy has been developed through review
More informationContinuous Glucose Monitoring
Continuous Glucose Monitoring What is Continuous Glucose Monitoring? Blood glucose meters measure glucose in your blood and glucose sensors measure glucose levels in the fluid around the cells They are
More informationINSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. MORE TIME HERE TO USING
More informationCGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117
CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current
More information